Sapropterin on Cognitive Abilities in Young Adults With Phenylketonuria
Sapropterin in Individuals With Phenylketonuria
Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU
Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU)
An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165
A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks
Nutritional Status in Phenylketonuria
BH4 Responsiveness in PAH Deficiency PKU Patients
A Non-Interventional Interview Study of Phenylketonuria (PKU) Adults
A Phase 3 Substudy to Evaluate Executive Function in Adults With PKU Who Are Participating in the Phase 3 Study, 165-302
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
Nutrition Status of Adults Treated With Pegvaliase
Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU
A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects
PKU Skin Stripping
Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)
AAV Gene Therapy Study for Subjects with PKU
Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKU
Observational Study on the Long Term Safety of Kuvan® Treatment in Patients With Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or BH4 Deficiency
The Effectiveness of Kuvan in Amish PKU Patients
You're leaving the BioMarin Clinical Trials website.
This will take you to BioMarin.com, our global corporate website. Some of the information on BioMarin.com is intended for U.S. audiences only.
